Drug Profile
OCV 101
Alternative Names: OTS-11101Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer OncoTherapy Science; Otsuka Pharmaceutical
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (SC, Injection)
- 08 Jun 2015 Phase-II development for Pancreatic cancer is ongoing in Japan
- 09 Jan 2015 Otsuka Pharmaceutical announces termination of its license agreement with OncoTherapy Science for OCV 101